Hims Jumps as FDA Compounding Case Status Report Is Delayed

Shares of Hims & Hers Health, a telehealth platform that sells compounded obesity drugs, jumped 11% on Thursday after a court document showed the FDA said it needed more time to determine if Eli Lilly & Co’s blockbuster compound, tirzepatide, should remain off the shortage list.

Read more: Lilly in Focus Ahead of FDA Report on Weight-Loss Drug Shortage

• A compounders group and the FDA, engaged in litigation over the tirzepatide shortage, agreed to extend the filing deadline of their joint status report, possibly until Dec. 19
  • Both parties were originally slated to file a status report by Nov. ...